Status:
COMPLETED
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
Lead Sponsor:
Emory University
Collaborating Sponsors:
Abbott
Conditions:
Senile Dementia, Alzheimer Type
Dementia, Alzheimer Type
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitatio...
Detailed Description
Previous researchers have attempted to establish a "target dose" for antipsychotic medications (such as risperidone, quetiapine, or olanzapine) in treating symptoms of agitation in dementia. They have...
Eligibility Criteria
Inclusion
- inpatients admitted to Wesley Woods Inpatient service for Dementia with psychosis and agitation; taking risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day)
Exclusion
- prior sensitivity to risperidone, quetiapine, olanzapine or divalproex
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00208819
Start Date
September 1 2003
End Date
July 1 2007
Last Update
November 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wesley Woods Geriatric Hospital
Atlanta, Georgia, United States, 30329